key: cord-1012246-n7nik3rq authors: Akter, Farhana; Mannan, Adnan; Mehedi, H.M. Hamidullah; Rob, Abdur; Ahmed, Shakeel; Salauddin, Asma; Hossain, Md Shakhawat; Hasan, Md Mahbub title: Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh date: 2020-10-21 journal: Diabetes Metab Syndr DOI: 10.1016/j.dsx.2020.10.016 sha: 7cb85de3ec1d9d50a2f60dd85bc68e950392db84 doc_id: 1012246 cord_uid: n7nik3rq BACKGROUND AND AIMS: This study investigated the clinical manifestations, outcomes and long-term complications of COVID-19 inpatients in Bangladesh while emphasizing on individuals having diabetes. METHODS: A cross-sectional study was conducted for a sample of COVID-19 inpatients across four different hospitals of Bangladesh between April 1st and June 30, 2020. Variation in clinical characteristics, contact history, comorbidities, treatment pattern, and long-term complications were investigated. RESULTS: There were 734 COVID-19 presentations in this study of which 19.8% of patients had diabetes and 76% of the COVID-19 patients were male. Among biochemical parameters, glucose, D-dimer, C- reactive protein (CRP) and Troponin levels were significantly elevated amidst the cohort with diabetes. The frequency of patients requiring insulin increased threefold during infection with SARS CoV2. A number of COVID-19 patients with diabetes have been suffering from long term complications post-recovery including pain, discomfort, memory loss and sleep disturbance. CONCLUSION: Individuals with diabetes have experienced a severe manifestation of COVID-19 and post disease complications. Further in-depth studies focused on larger sample sizes are entailed to assess the relationships elaborately. 63 COVID-19 is an infectious, contagious disease of the respiratory system caused by a varying, 64 novel strain of the Severe acute respiratory syndrome-related coronavirus (SARS-CoV) 65 known as the Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) [1] . 66 Since the inception of its outbreak in Wuhan, China at the end of December 2019, COVID-19 67 increased its host span in a rapid progression globally and therefore was declared a pandemic 68 by the WHO on March 11, 2020 [1, 2] . 69 SARS-CoV-2 is an enveloped, beta coronavirus consisting of a single-stranded positive-sense 70 RNA (23-32kb) as its core genetic material [3] . SARS-CoV-2 generally spreads through 71 Human-to-human transmission (HHT) by means of respiratory droplets through direct contact 72 or fomite and aerosols [4, 5] . COVID-19 has a diversified pattern in terms of symptoms, 73 recovery rate and mortality rates across the globe. Predominant manifestations of mild flu-74 like symptoms, shortness of breath, depleted sense of taste and smell were found in the 75 majority of COVID-19 patients [6, 7] ; however in some, there were no symptoms at all while 76 in others, the disease either progressed towards more severe clinical complexities including 77 Pneumonia [8, 9] , Acute Respiratory Distress Syndrome (ARDS), multi-organ failure or 78 became lethal [2] . The prospect of risk factor in the case of COVID-19 with regards to age 79 nevertheless is still vague since the disease has been diagnosed in people in almost every age 80 group. Case-control studies conducted on COVID-19 during the pandemic concluded that 82 comorbidity (persistence of medical conditions including obesity, hypertension and diabetes 83 mellitus) could be a determinant on the progression of COVID-19 in individuals [10] . 84 Although the data is quite limited, recent studies have put forward that the prevalence of 85 diabetes mellitus (DM) and elevated blood glucose levels can act as independent factors of 86 mortality and morbidity related to COVID-19; firstly because individuals with diabetes have 87 a prolonged recovery duration from viral diseases due to having a compromised immune 88 system and secondly for the virus's ability to sustain itself in an environment with high 89 glucose levels putting individuals with diabetes mellitus at a vulnerable position from the 90 aspect of casualties due to . Additionally, some recent studies proclaimed 91 a number of COVID-19 associated long term complications [14, 15] which require further 92 investigation and assessment to establish facts in detail. The presence or absence of SARS-CoV-2 infection and by extension, a positive or negative 143 case of COVID-19 was confirmed by RT-PCR assay. Individuals who resided in the hospitals 144 for more than 24 hours were considered to be inpatients. Cases having glycated haemoglobin 145 (HbA1c) content of 6.5% who went through any approved biochemical assessment of 146 diabetes mellitus previously were considered within the group having diabetes. Two or more 147 blood glucose level assessments which returned a result greater than 11.1 mmol/l defined 148 uncontrolled hyperglycemia; contrary to which blood glucose levels < 4 mmol/l classified as 149 hypoglycaemia. Samples were split depending on them having or not having diabetes 150 considering medication itinerary of antidiabetic drugs or fasting blood glucose level during 151 admittance in the hospital as determinants. A total of 734 patients diagnosed with COVID-19 were interviewed for this study. A relevant 156 questionnaire and medical records were taken into account as the principal sources of data. In through self-reporting as well as records. All retrospective data collected by physicians over 159 telephone interviews were manually put into a Google Form. All information added on the 160 form which represented answers given by the subjects were double-checked, submitted and 161 the records were preserved. The questionnaire in use asked for a patient's socio-demographic 162 information, clinical manifestations, biochemical parameters, behavioural practices, 163 comorbidities, medication types, laboratory tests, electrocardiogram results, inpatient 164 medications, treatments and outcomes (including the length of stay in the hospital, discharge, 165 re-admission, and mortality). and without diabetes significantly varied among different age groups (p= 0.000) ( Table-1 ). Although one-third of the COVID-19 patients with diabetes belonged to the elder age group 200 (≥ 60 years), the persistence of COVID-19 was higher in the patients not exceeding 39 years 201 of age and without diabetes ( Table-1 ). The number of male patients (76%) was three times 202 higher than female patients (24%) regardless of them being with or without diabetes. In the 203 dataset, the most frequently occurring blood groups among patients with diabetes were B+ 204 (35%) and O+ (31%), while there were no A-and B-blood groups among the individuals. The prevalence of COVID-19 cases was found to be comparatively higher in the urban area 206 (70%). Monthly gross family income and the burden of diabetes among COVID-19 patients 207 were significantly correlated (p=0.000). We found that about 40% COVID-19 patients 208 belonged to middle-income families with a gross monthly income between BDT 25,000 and 209 BDT 49,999 (296-590 USD). Interesting enough, COVID-19 patients from the low-income 210 tier had a lower burden of diabetes (18.5% vs 30.4%) whereas the high-income group had 211 almost double the burden of diabetes (23.3% vs 11.2%). There were no significant 212 differences in terms of being vaccinated or not vaccinated among patients with and without 213 diabetes. The majority of COVID-19 cases were found to have been administered with all 214 vaccines (91%) and BCG vaccine (85%) but this does not have any impact on the outcome of 215 the disease depending on them having diabetes or not having diabetes. The most common 216 comorbidities were cardiovascular diseases (24%), respiratory diseases (11%), and history of 217 heart attack (10%) in patients with diabetes. Moreover the frequency of comorbidities, cancer 218 (3.4% vs 0.9%, p=0.016), cardiovascular disease (24% vs 5.4%, p=0.000), respiratory disease 219 (11% vs 5%, p= 0.007), liver disease (5.5% vs 1%, p=0.002), history of heart attack (10% vs 220 0.71%, p=0.000) and other chronic disease (14% vs 6.5%, p=0.004) are statistically 221 significant in COVID-19 patients with diabetes (Table-1) . 222 We tried to trace their contact with any confirmed COVID-19 patients directly, indirectly or COVID-19 patients before being infected and 39 (5.3%) had contact with foreign returnees 227 ( Table 2 . 8.9% (n=64) was asymptomatic and among them, 254 COVID-19 patients without diabetes (10%, n= 59) were significantly higher (p=0.024) than 255 that of the patients with diabetes (4.1%, n=6). The most common symptoms observed on the onset of the disease, regardless of ages and 257 sex, were persistent fever (75.5%, n=554), cough (57.4%, n=421), loss of taste (43.5%, 258 n=319), aches and pain (40.1%, n= 294), loss of smell 39.8% (n=292). Persistent fever (temperature > 38°C) was observed in 75.5% (n=554) patients extending beyond 1 day. It 260 was significantly higher (P < 0.05) in patients with diabetes (89.7%, n=131) than that of the 261 patients without diabetes (71.9%, n=423). Among 195 (26.6%) SARS-CoV-2 positive 262 patients, breathing difficulties including shortness of breath and/or rapid breathing was also 263 significantly higher in COVID-19 patients with diabetes (57, 39%) than that in patients 264 without diabetes (n= 138, 23.5%). For symptoms, no significant deviations were found when compared between COVID-19 266 patients with and without diabetes such as chills, chest pain, cough, aches and pain, sore Figure S1 ). In this study, various biochemical and hematological parameters were scrutinized among 276 COVID-19 patients with diabetes and without diabetes ( Troponin (43.2% vs 15%) and the Total count of WBC, ESR were significantly (P<0.05) 280 higher in COVID-19 patients with diabetes than those without diabetes. However, the degree 281 of serum uric acid was lower in COVID-19 cases with diabetes. The TC counts of WBC of 282 most of the patients were in the normal range, but the classified count showed that the TC 283 counts of COVID-19 patients with diabetes were significantly higher than those without 284 diabetes. Although the platelet count of most of the patients was within the normal range, the 285 categorical data showed that it was significantly (P <0.05) higher among the COVID-19 286 cases with diabetes. Compared to cases without diabetes, the level of D-dimer, troponin and 287 CRP was significantly higher in patients with diabetes with no significant differences in the 288 level of Ferritin and SGPT. However, more than 60% of the COVID-19 cases with and 289 without diabetes were found to have more high Ferritin levels. The percentage of cases with diabetes taking insulin as an aid dramatically increased (more 294 than three times) when diagnosed with COVID-19. Before being infected, only 18% of the 295 individuals took insulin shots, which increased very promptly to 63% post-COVID-19 296 diagnosis (Figure-1) . On the contrary, the percentage of intake of other medications related to 297 diabetes by COVID-19 patients except for insulin such as Biguanide and Sulfonylurea 298 decreased from 44% to 29% and from 11% to 4% respectively. Besides, intake of DPP4 299 inhibitors and other drugs were also decreased from 2% to 1%. To the best of our knowledge, this study pioneered in investigating the clinical characteristics 326 and prognosis of COVID-19 patients with diabetes in Bangladesh. For the past few decades, 327 the prevalence of diabetes mellitus in Bangladesh has been on the rise. Although previous 328 studies reported a 9% to 14% prevalence of diabetes in 18, 19] , our 329 study concluded on a higher prevalence rate for the same (19.89%).. Larger proportion of 330 geriatric patients in our sample might contribute this higher prevalence rate. Similar to 331 previous studies in other regions [20, 21] our study also found that 76% of the diagnosed 332 cases were males and that the frequency of COVID-19 was significantly higher in individuals 333 with diabetes aged 40 and higher. Apart from diabetes mellitus, cardiovascular diseases 334 (24%), respiratory diseases (11%) and chronic diseases were common. Nuance in expression of blood group antigen can either elevate or reduce host susceptibility 336 to infections caused by Helicobacter pylori, Norwalk virus, and SARS-CoV etc by serving as 337 receptors and/or co-receptors for pathogens [22] . In this study, we found B+ and O+ blood 338 groups were prevalent among patientsB+O+, whereas A-and B-had a lower frequency. B(+) 339 ve and O+ blood group has previously been reported as the most common blood group 340 among Bangladeshis [23] which could be a contributing reason for the higher prevalence. However, some global studies reported that blood group A was associated with COVID-19 342 compared to non-A blood groups [24, 25] . Our study did not find any similar relationship in 343 regards to the aforesaid fact. The clinical manifestations of COVID-19 were almost similar in the group with and without 345 diabetes (Table 2) . According to the present study, the occurrence of asymptomatic infection 346 is less in COVID-19 patients with diabetes. The compromised immune response among cases 347 with diabetes has been reported to play a role in disease expression and progression [26] and 348 that can be a strong determinant for the higher frequency of symptomatic COVID-19 cases. Common symptoms in both groups regardless of age and sex were fever, cough, aches and Biochemical diagnostic assays reported that significantly greater hyperglycemia was 365 observed in patients with diabetes than those without (Table 2 ). In cases with diabetes, we Compared with COVID-19 patients without diabetes, Troponin-1 was also found to be 380 present at significantly higher levels in those with diabetes ( shed light upon and thus calls for further analyses and cohorts to assess. The frequency of patients taking insulin during COVID-19 increased more than three-fold in 392 terms of the intake frequency before COVID-19 occurrence (Figure 1 ). In patients with DM, and insomnia (13%). Notably, insomnia, memory loss, anxiety, and depression were 425 relatively common, suggesting that although a full syndrome of mania was uncommon, 426 subthreshold symptoms might be present. However, the common symptoms that were 427 reported to be highly prevalent (such as depression, anxiety, loss of concentration, memory 428 loss and fatigue) could implore selection bias and be irrelevant to SARS-CoV-2 infection. Since our study results were based on cohort information, it was not confirmed by any 430 professionals. So further psychiatric, clinical and molecular research is required to explain the 431 mechanism of various abnormalities due to COVID-19. Figure S1 . The pattern of symptoms of COVID-19 in different age groups (n=734). Virology, epidemiology, pathogenesis, and control of COVID-19. 529 Viruses COVID-19 and diabetes: 531 Knowledge in progress Severe respiratory SARS-CoV2 infection: Does ACE2 receptor 533 matter? Respiratory Medicine Epidemiology, causes, clinical manifestation and diagnosis, 535 prevention and control of coronavirus disease (COVID-19) during the early outbreak 536 period: a scoping review. Infectious diseases of poverty First respiratory transmitted food borne outbreak? International journal of 538 hygiene and environmental health Association of diabetes mellitus with disease severity and prognosis 540 in COVID-19: A retrospective cohort study. Diabetes Research and Clinical Practice Presenting characteristics, comorbidities, and outcomes 543 among 5700 patients hospitalized with COVID-19 in the New York City area Subjective neurological symptoms frequently occur in patients with 546 SARS-CoV2 infection Cytokine storm intervention in the early stages of COVID-19 548 pneumonia Clinical characteristics and outcomes of COVID-19 hospitalized 550 patients with diabetes in UK: A retrospective single centre study. Diabetes Research 551 and Clinical Practice COVID-19 pandemic, coronaviruses, and diabetes 553 mellitus Prevalence and impact of diabetes among people infected with 556 SARS-CoV-2 Diabetes is a risk factor for the progression and prognosis of COVID-558 19 Persistent symptoms in patients after acute 560 COVID-19 Planning for the Post-COVID Syndrome: How Payers 562 Can Mitigate Long-Term Complications of the Pandemic World population prospects 2019: Highlights. United Nations Department for 565 Economic and Social Affairs Global and regional diabetes prevalence estimates for 2019 and 567 projections for 2030 and 2045: Results from the International Diabetes Federation 568 Diabetes Atlas. Diabetes research and clinical practice The effect of chronic pain on diabetes patients' self-management. 570 Diabetes care Vitamin D can prevent COVID-19 infection-induced multiple organ 572 damage. Naunyn-schmiedeberg's Archives of Pharmacology Clinical characteristics of 138 hospitalized patients with 2019 novel 574 coronavirus-infected pneumonia in Wuhan, China Clinical characteristics of 140 patients infected with SARS-CoV-2 577 in Wuhan Blood groups in infection and host susceptibility Distribution of phenotypic and genotypic ABO and Rhesus blood 581 groups among Bangladeshi population Relationship between ABO blood group distribution and clinical 584 characteristics in patients with COVID-19 COVID-19 & ABO blood group: another 587 viewpoint Factors Leading to High Morbidity and 589 Mortality of COVID-19 in Patients with Type 2 Diabetes Are patients with hypertension and diabetes 591 mellitus at increased risk for COVID-19 infection? The Lancet. Respiratory Medicine Practical recommendations for the management of diabetes in 594 patients with COVID-19. The lancet Diabetes & endocrinology Does comorbidity increase the risk of patients with COVID-19: 596 evidence from meta-analysis Characteristics and outcomes of COVID-19 in hospitalized 598 patients with and without diabetes Diabetes epidemiology in the COVID-19 pandemic. 601 Diabetes care Clinical characteristics of coronavirus disease 2019 in China 603 Risk factors associated with acute respiratory distress syndrome and 605 death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA 606 internal medicine Clinical course and outcomes of critically ill patients with SARS-CoV-608 2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. 609 The Lancet Respiratory Medicine Clinical Characteristics of Diabetic Patients with COVID-19 Elevated troponin in patients with Coronavirus Disease 2019 613 (COVID-19): possible mechanisms Evidence for a local angiotensin-generating 615 system and dose-dependent inhibition of glucose-stimulated insulin release by 616 angiotensin II in isolated pancreatic islets COVID-19 infection in Italian people with 618 diabetes: Lessons learned for our future (an experience to be used). diabetes 619 research and clinical practice COVID-19 and Diabetes: Insulin 621 Requirements Parallel Illness Severity in Critically Unwell Patients Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 624 and Diabetes Mellitus: A Practical Approach Management of hyperglycemia in hospitalized patients in 627 non-critical care setting: an endocrine society clinical practice guideline The association between metformin therapy and lactic acidosis. 630 Drug Safety SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 632 diabetes: systematic review and meta-analysis of randomized controlled trials Diagnosis, treatment, and prevention of 2019 novel coronavirus 635 infection in children: experts' consensus statement Psychiatric and neuropsychiatric presentations associated with 638 severe coronavirus infections: a systematic review and meta-analysis with 639 comparison to the COVID-19 pandemic. The Lancet Psychiatry J o u r n a l P r e -p r o o f The authors would like to declare that there is no known contending financial interests or personal relationships that could affect the work reported in this paper.